Nouscom

Nouscom is a private, clinical-stage biotech company pioneering viral vector-based cancer immunotherapies. Its core technology utilizes engineered adenovirus (GAd) and Modified Vaccinia Ankara (MVA) vectors to deliver long strings of tumor neoantigens, aiming to generate potent and specific T-cell responses against cancer. The company's pipeline features two lead clinical programs: NOUS-209, an off-the-shelf vaccine for mismatch repair deficient (dMMR) tumors and Lynch syndrome, and NOUS-PEV, a personalized neoantigen vaccine. With a seasoned leadership team experienced in viral vaccine development and a platform validated in over 4,000 subjects for infectious diseases, Nouscom is positioned to advance novel treatments in the growing cancer vaccine market.

Proprietary engineered viral vectors (Great Ape Adenovirus/GAd and Modified Vaccinia Ankara/MVA) optimized to encode and deliver long strings of tumor neoantigens for inducing potent anti-tumor T cell responses.

Nouscom operates in the highly competitive cancer vaccine and neoantigen therapy arena, competing with other biotechs like BioNTech, Moderna (mRNA platforms), Gritstone bio, and large pharma companies. Its differentiation lies in its viral vector platform's proven immunogenicity and capacity to deliver many neoantigens, and its dual off-the-shelf/personalized strategy.